PPARβ/δ protects against experimental colitis through a ligand-independent mechanism

Digestive Diseases and Sciences

Volumn 52, Issue 11, 2007, Pages 2912-2919

  Hollingshead, Holly E ^a   Morimura, Keiichirou ^b   Adachi, Masahiro ^b   Kennett, Mary J ^a   Billin, Andrew N ^c   Willson, Timothy M ^c   Gonzalez, Frank J ^b   Peters, Jeffrey M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Colitis; Inflammatory bowel disease; Peroxisome proliferator activated receptor (PPAR)

Indexed keywords

DEXTRAN; GAMMA INTERFERON; INTERLEUKIN 6; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; TUMOR NECROSIS FACTOR ALPHA; DEXTRAN SULFATE; GW0742; LIGAND; MESSENGER RNA; PEROXIDASE; PLASMA SUBSTITUTE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENOTYPE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COLON; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; GENETICS; HOSPITALIZATION; INTESTINE CELL; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION;

ANIMALS; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENTEROCYTES; FEMALE; GENE EXPRESSION; INTERFERON TYPE II; INTERLEUKIN-6; LIGANDS; MICE; MICE, INBRED C57BL; PEROXIDASE; PLASMA SUBSTITUTES; POLYMERASE CHAIN REACTION; PPAR DELTA; PPAR-BETA; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34848838350     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9644-9     Document Type: Article

References (46)

1. Bouma G, Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nature Rev Immunol 3:521-533
2. Podolsky D (2002) Inflammatory bowel disease. N Engl J Med 347:417-429
3. Strober W (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20:495-549
4. Carpentier I, et al. (1998) TRAF2 plays a dual role in NF-kappaB-dependent gene activation by mediating the TNF-induced activation of p38 MAPK and IkappaB kinase pathways. FEBS Lett 425(2):195-198
5. Hirano M, Aoki T, Hirai S, Hosaka M, Inoue J, Ohno S (1996) MEK kinase is involved in tumor necrosis factor alpha-induced NF-kappaB activation and degradation of IkappaB-alpha. J Biol Chem 271(22):13234-13238
6. Daynes R, Jones DC (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2:748-759
7. Youssef J, Badr M (2004) Role of peroxisome proliferator-activated receptors in inflammation control. J Biomed Biotech 3:156-166
8. Castrillo A, Tontonoz P (2004) Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 20:455-480
9. Michalik L, Desvergne B, Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4(1):61-70
10. Molnar F, Carlberg C (2005) Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. J Biol Chem 280(28):26543-26556
11. Lee CH, et al. (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302(5644):453-457
12. Marx N, et al. (2001) PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 103(2):213-219
13. Shu H, et al. (2000) Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 267(1):345-349
14. Devchand PR, et al. (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384(6604):39-43
15. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391(6662):82-86
16. Ricote M, et al. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391(6662):79-82
17. Yang XY, et al. (2000) Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 275(7):4541-4544
18. Su CG, et al. (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104(4):383-389
19. Welch J, Ricote M, Akiayama TE, Gonzalez FJ, Glass CK (2003) PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA 100:6712-6717
20. Setoguchi K, et al. (2001) Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest 108(11):1667-1675
21. Kim DJ, Billin AN, Willson TM, Gonzalez FJ, Peters JM (2006) PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Different 13(1):53-60
22. Schmuth M, et al. (2004) Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 122(4):971-983
23. Peters JM, et al. (2000) Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor b(d). Mol Cell Biol 20:5119-5128
24. Cuzzocrea S, Di Paola R, Mazzon E, Tiziana G, Muia C, Centorrino T, Caputi AP (2004) Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha in the development of inflammatory bowel diesease in mice. Lab Invest 84:1643-1654
25. Saubermann LJ, et al. (2002) Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 8(5):330-339
26. Desreumaux P, et al. (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193(7):827-838
27. Nakajima A, et al. (2001) Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120(2):460-469
28. Dubuquoy L, et al. (2002) Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 360(9343):1410-1418
29. Katayama K, et al. (2003) A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 124(5):1315-1324
30. Bassaganya-Riera J, et al. (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127(3):777-791
31. Takagi T, Naito Y, Ichikawa H, Tomatsure N, Katada K, Isozaki Y, Kuroda M, Kokura S, Yoshida N, Yoshikawa T (2004) A PPAR-gamma ligand, 15-deoxy-Delta 12,14-prostaglandin J(2), inhibited gastric mucosal injury induced by ischemia-reperfusion in rats. Redox Rep 9:376-381
32. Schaefer KL, et al. (2005) Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 11(3):244-252
33. Lytle C, et al. (2005) The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 11(3):231-243
34. Adachi M, Kurotani R, Morimura M, Shah Y, Sanford M, Madison BB, Gumico DL, Marin HE, Peters JM, Young HA, Gonzalez FJ (2000) PPAR-gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55(8):1104-1113
35. Bassaganya-Riera J, Hontecillas R (2006) CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr (in press)
36. Wallace JL, et al. (1992) Mechanisms underlying the protective effects of interleukin 1 in experimental nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 102(4; Pt 1):1176-1185
37. Cooper HS, et al. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69(2):238-249
38. Kim DJ, et al. (2004) Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 279(22):23719-23727
39. Rokos CL, Ledwith BJ (1997) Peroxisome proliferators activate extracellular signal-regulated kinases in immortalized mouse liver cells. J Biol Chem 272(20):13452-13457
40. Papadakis KA (2004) Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep 4(1):83-89
41. Huin C, et al. (2000) Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract. J Histochem Cytochem 48(5):603-611
42. Shi Y, Hon M, Evans RM (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 99(5):2613-2618
43. Lewis J, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie DJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD (2001) An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 96:3323-3328
44. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM (2006) Ligand activation of PPARbeta/delta inhibits colon carcinogenesis. Cancer Res 66(8):4394-4401
45. Ding G, et al. (2006) PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol (in press)
46. Gupta RA, et al. (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 97(24):13275-13280